COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity
The administration of COVID-19 vaccines is the primary strategy used to prevent further infections by COVID-19, especially in people living with HIV (PLWH), who are at increased risk for severe symptoms and mortality. However, the vaccine hesitancy, safety, and immunogenicity of COVID-19 vaccines am...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/12/1458 |
| _version_ | 1797500075193139200 |
|---|---|
| author | Ying Liu Junyan Han Xin Li Danying Chen Xuesen Zhao Yaruo Qiu Leidan Zhang Jing Xiao Bei Li Hongxin Zhao |
| author_facet | Ying Liu Junyan Han Xin Li Danying Chen Xuesen Zhao Yaruo Qiu Leidan Zhang Jing Xiao Bei Li Hongxin Zhao |
| author_sort | Ying Liu |
| collection | DOAJ |
| description | The administration of COVID-19 vaccines is the primary strategy used to prevent further infections by COVID-19, especially in people living with HIV (PLWH), who are at increased risk for severe symptoms and mortality. However, the vaccine hesitancy, safety, and immunogenicity of COVID-19 vaccines among PLWH have not been fully characterized. We estimated vaccine hesitancy and status of COVID-19 vaccination in Chinese PLWH, explored the safety and impact on antiviral therapy (ART) efficacy and compared the immunogenicity of an inactivated vaccine between PLWH and healthy controls (HC). In total, 27.5% (104/378) of PLWH hesitated to take the vaccine. The barriers included concerns about safety and efficacy, and physician counselling might help patients overcome this vaccine hesitancy. A COVID-19 vaccination did not cause severe side effects and had no negative impact on CD4<sup>+</sup> T cell counts and HIV RNA viral load. Comparable spike receptor binding domain IgG titer were elicited in PLWH and HC after a second dose of the CoronaVac vaccine, but antibody responses were lower in poor immunological responders (CD4<sup>+</sup> T cell counts < 350 cells/µL) compared with immunological responders (CD4<sup>+</sup> T cell counts ≥ 350 cells/µL). These data showed that PLWH have comparable safety and immune response following inactivated COVID-19 vaccination compared with HC, but the poor immunological response in PLWH is associated with impaired humoral response. |
| first_indexed | 2024-03-10T03:56:38Z |
| format | Article |
| id | doaj.art-fa80452fd7de4d92888e49dbcf7de94d |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T03:56:38Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-fa80452fd7de4d92888e49dbcf7de94d2023-11-23T10:54:38ZengMDPI AGVaccines2076-393X2021-12-01912145810.3390/vaccines9121458COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and ImmunogenicityYing Liu0Junyan Han1Xin Li2Danying Chen3Xuesen Zhao4Yaruo Qiu5Leidan Zhang6Jing Xiao7Bei Li8Hongxin Zhao9Clinical Center for HIV/AIDS, Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, ChinaBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, ChinaDepartment of Center of Integrated Traditional Chinese and Western Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, ChinaBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, ChinaBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, ChinaClinical Center for HIV/AIDS, Clinical and Research Center of Infectious Diseases, Peking University Ditan Teaching Hospital, Beijing 100015, ChinaClinical Center for HIV/AIDS, Clinical and Research Center of Infectious Diseases, Peking University Ditan Teaching Hospital, Beijing 100015, ChinaClinical Center for HIV/AIDS, Clinical and Research Center of Infectious Diseases, Peking University Ditan Teaching Hospital, Beijing 100015, ChinaClinical Center for HIV/AIDS, Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, ChinaClinical Center for HIV/AIDS, Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, ChinaThe administration of COVID-19 vaccines is the primary strategy used to prevent further infections by COVID-19, especially in people living with HIV (PLWH), who are at increased risk for severe symptoms and mortality. However, the vaccine hesitancy, safety, and immunogenicity of COVID-19 vaccines among PLWH have not been fully characterized. We estimated vaccine hesitancy and status of COVID-19 vaccination in Chinese PLWH, explored the safety and impact on antiviral therapy (ART) efficacy and compared the immunogenicity of an inactivated vaccine between PLWH and healthy controls (HC). In total, 27.5% (104/378) of PLWH hesitated to take the vaccine. The barriers included concerns about safety and efficacy, and physician counselling might help patients overcome this vaccine hesitancy. A COVID-19 vaccination did not cause severe side effects and had no negative impact on CD4<sup>+</sup> T cell counts and HIV RNA viral load. Comparable spike receptor binding domain IgG titer were elicited in PLWH and HC after a second dose of the CoronaVac vaccine, but antibody responses were lower in poor immunological responders (CD4<sup>+</sup> T cell counts < 350 cells/µL) compared with immunological responders (CD4<sup>+</sup> T cell counts ≥ 350 cells/µL). These data showed that PLWH have comparable safety and immune response following inactivated COVID-19 vaccination compared with HC, but the poor immunological response in PLWH is associated with impaired humoral response.https://www.mdpi.com/2076-393X/9/12/1458HIVCOVID-19SARS-CoV-2 vaccinevaccine hesitancysafetyimmunogenicity |
| spellingShingle | Ying Liu Junyan Han Xin Li Danying Chen Xuesen Zhao Yaruo Qiu Leidan Zhang Jing Xiao Bei Li Hongxin Zhao COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity Vaccines HIV COVID-19 SARS-CoV-2 vaccine vaccine hesitancy safety immunogenicity |
| title | COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity |
| title_full | COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity |
| title_fullStr | COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity |
| title_full_unstemmed | COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity |
| title_short | COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity |
| title_sort | covid 19 vaccination in people living with hiv plwh in china a cross sectional study of vaccine hesitancy safety and immunogenicity |
| topic | HIV COVID-19 SARS-CoV-2 vaccine vaccine hesitancy safety immunogenicity |
| url | https://www.mdpi.com/2076-393X/9/12/1458 |
| work_keys_str_mv | AT yingliu covid19vaccinationinpeoplelivingwithhivplwhinchinaacrosssectionalstudyofvaccinehesitancysafetyandimmunogenicity AT junyanhan covid19vaccinationinpeoplelivingwithhivplwhinchinaacrosssectionalstudyofvaccinehesitancysafetyandimmunogenicity AT xinli covid19vaccinationinpeoplelivingwithhivplwhinchinaacrosssectionalstudyofvaccinehesitancysafetyandimmunogenicity AT danyingchen covid19vaccinationinpeoplelivingwithhivplwhinchinaacrosssectionalstudyofvaccinehesitancysafetyandimmunogenicity AT xuesenzhao covid19vaccinationinpeoplelivingwithhivplwhinchinaacrosssectionalstudyofvaccinehesitancysafetyandimmunogenicity AT yaruoqiu covid19vaccinationinpeoplelivingwithhivplwhinchinaacrosssectionalstudyofvaccinehesitancysafetyandimmunogenicity AT leidanzhang covid19vaccinationinpeoplelivingwithhivplwhinchinaacrosssectionalstudyofvaccinehesitancysafetyandimmunogenicity AT jingxiao covid19vaccinationinpeoplelivingwithhivplwhinchinaacrosssectionalstudyofvaccinehesitancysafetyandimmunogenicity AT beili covid19vaccinationinpeoplelivingwithhivplwhinchinaacrosssectionalstudyofvaccinehesitancysafetyandimmunogenicity AT hongxinzhao covid19vaccinationinpeoplelivingwithhivplwhinchinaacrosssectionalstudyofvaccinehesitancysafetyandimmunogenicity |